RNS Number : 5270D MaxCyte, Inc. 03 March 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 1158D MaxCyte, Inc. 01 March 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Block Listing Return Gaithersburg, Maryland - 1 March 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes
RNS Number : 7185C MaxCyte, Inc. 24 February 2022 MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022 GAITHERSBURG, MD , February 24, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing
RNS Number : 4691C MaxCyte, Inc. 22 February 2022 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name MAXCYTE, INC. UK or Non- UK Issuer Non- UK 2. Reason for Notification An acquisition or disposal of voting rights 3.
RNS Number : 2025C MaxCyte, Inc. 21 February 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Consolidation of Trading Lines Total voting rights Gaithersburg, Maryland - 21 February 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform
RNS Number : 5088B MaxCyte, Inc. 14 February 2022 MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , February 14, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies
RNS Number : 5087B MaxCyte, Inc. 14 February 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , February 14, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 2329A MaxCyte, Inc. 01 February 2022 MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs Intima Bioscience to use
RNS Number : 3037Z MaxCyte, Inc. 24 January 2022 MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results · Fourth quarter 2021 revenue expected to be greater than $10 million · Full year 2021 revenue expected to be greater than $33.7
RNS Number : 9767W MaxCyte, Inc. 29 December 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
